Clarivate
See how financing, partnerships and M&A are shifting in a more selective market ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
Biotech deals outlook 2026: What’s changed — and what’s next
Get the report and webinar on deal trends shaping biotech strategy in 2026
Get the full outlook
Dear dupa,

After years of volatility, biotech dealmaking is turning a corner. Capital is returning — but with greater selectivity. Investors and pharma are prioritizing fewer, larger deals, while reshaping how they partner, license, and source innovation globally.
Get the Biopharma Deals & Financing Outlook 2026 — including a new report and on-demand webinar — for a clear, data-backed view of where the market is heading. 
 
Inside the report and webinar: 
  • $292.6bn in deal activity — what record levels reveal about shifting growth priorities 
  • Fewer, larger partnerships — how deal size and structure are evolving 
  • Global innovation sourcing — including China’s growing role in licensing and collaboration 
  • Where capital is concentrating most — oncology, immunology, metabolic disease, RNA and next-gen modalities 
  • What this means for BD strategy — how to position for partnerships, capital access and deals in a more selective market 
Get the full outlook
Built with insights from Clarivate and BioWorld, this report and webinar provide a practical view of how biotech financing and dealmaking are evolving — and what teams need to do next. 
Learn more.
Clarivate Twitter Clarivate Facebook Clarivate Linkedin

This is a sponsored email from Clarivate sent by Endpoints (2029 Becker Drive, Lawrence, KS 66047 USA) from an account we use for sending messages only.

Want to send your own email like this to Endpoints News subscribers? Please contact Melissa Nazzaro instead of replying to this email: melissa@endpointsnews.com.

No longer wish to receive certain emails from Endpoints? You may update your unsubscribe preferences or upgrade to an Insider subscription for the option to disable sponsored messages.

Unsubscribe entirely from all news and sponsored posts by clicking the link below: Unsubscribe